Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

NCT04915612 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

1

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia

Interventions

DRUG: Gemtuzumab Ozogamicin
DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Sponsor

M.D. Anderson Cancer Center